JAMA Oncology Publication Demonstrates EndoPredict Significantly Outperforms Oncotype DX

Myriad Genetics (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.  A key finding is that Myriad’s EndoPredict^® (EPClin) significantly outperformed Oncotype DX^® Recurrence Score at predicting the risk of disease recurrence in patients with early-stage breast cancer.

As quoted in the press release:

“This study demonstrates that EndoPredict, which combines a multigene signature with clinical information, significantly improves the prediction of disease recurrence, specifically in women with node-positive breast cancer,” said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.  “What this means is that EndoPredict can more accurately identify a larger percentage of patients who can safely forgo adjuvant chemotherapy and the associated toxicity.”

Click here to read the full press release.